Journey Medical (DERM) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nkarta (NKTX) has outperformed Journey Medical (DERM) over the past year, gaining 6.2% versus a loss of 21.2%. Journey Medical is the larger company by market cap ($167.9 million vs $159.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | NKTX |
|---|---|---|
| Share price | $5.95 | $2.22 |
| Market cap | $167.94M | $159.01M |
| 1-day change | 0.00% | -2.20% |
| YTD return | -22.83% | +20.00% |
| 1-year return | -21.19% | +6.22% |
| 5-year return | — | -87.90% |
| EPS (TTM) | $-0.22 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $3.72 |
| 52-week low | $4.31 | $1.70 |
| Distance from 52-week high | -37.73% | -40.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +131.09% | +387.84% |
| Average volume | 182.16K | 617.86K |
| Shares outstanding | 22.22M | 71.62M |
| Employees | 58 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed DERM by 27.4 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
DERM vs NKTX FAQ
Which is bigger, Journey Medical or Nkarta?
Journey Medical (DERM) is larger, with a market capitalization of $167.94M compared with $159.01M for Nkarta (NKTX).
Which stock has performed better over the past year, DERM or NKTX?
NKTX returned +6.22% over the past 12 months, compared with -21.19% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.